Open Access

Role of glutathione‑S‑transferase gene P1 in the diagnosis of prostate cancer in patients with ‘grey level’ prostate‑specific antigen values

  • Authors:
    • Marius Stan
    • Vladimir Botnarciuc
    • Andra-Iulia Suceveanu
    • Laura Mazilu
    • Daniel Ovidiu Costea
    • Adrian-Paul Suceveanu
    • Dragos Serban
    • Corneliu Tudor
    • Anca Mitroi
    • Costel Brinzan
    • Felix Voinea
  • View Affiliations

  • Published online on: July 26, 2022     https://doi.org/10.3892/etm.2022.11528
  • Article Number: 591
  • Copyright: © Stan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Prostate cancer (PC) represents the second most frequent cancer diagnosis in men and, at the same time, is one of the top six causes of death worldwide. The aim of the present study was to evaluate the diagnostic value of glutathione‑S‑transferase gene P1 (GST‑P1) in patients that fall within the ‘grey area’ of the prostate‑specific antigen (PSA) values. A retrospective observational study on 80 patients with prostate abnormal volumes and PSA values in the range 4‑10 ng/ml was performed. The prostate gland was extracted following transrectal ultrasonography, and GST‑P1 gene expression was analysed. A histopathological examination was considered the gold standard for PC diagnosis. Among the 53 patients diagnosed with PC, 69.8% (n=37) were GST‑P1‑positive, whereas, among the 27 patients diagnosed with benign prostatic hyperplasia, 18.5% (n=5) were GST‑P1‑positive. The sensitivity for diagnosing PC in patients with PSA values between 4 and 10 ng/ml was 69.81%, and the specificity was 81.48%. The positive predictive value was 88.1% [95% confidence interval (CI), 74.37‑96.02%] and the negative predictive value was 57.89% (95% CI, 40.82‑73.69%). Collectively, these results show the potential of using GST‑P1 gene expression in patients who are suspected of having PC, but where the PSA values are inconclusive.

Related Articles

Journal Cover

September-2022
Volume 24 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Stan M, Botnarciuc V, Suceveanu A, Mazilu L, Costea D, Suceveanu A, Serban D, Tudor C, Mitroi A, Brinzan C, Brinzan C, et al: Role of glutathione‑S‑transferase gene P1 in the diagnosis of prostate cancer in patients with ‘grey level’ prostate‑specific antigen values. Exp Ther Med 24: 591, 2022
APA
Stan, M., Botnarciuc, V., Suceveanu, A., Mazilu, L., Costea, D., Suceveanu, A. ... Voinea, F. (2022). Role of glutathione‑S‑transferase gene P1 in the diagnosis of prostate cancer in patients with ‘grey level’ prostate‑specific antigen values. Experimental and Therapeutic Medicine, 24, 591. https://doi.org/10.3892/etm.2022.11528
MLA
Stan, M., Botnarciuc, V., Suceveanu, A., Mazilu, L., Costea, D., Suceveanu, A., Serban, D., Tudor, C., Mitroi, A., Brinzan, C., Voinea, F."Role of glutathione‑S‑transferase gene P1 in the diagnosis of prostate cancer in patients with ‘grey level’ prostate‑specific antigen values". Experimental and Therapeutic Medicine 24.3 (2022): 591.
Chicago
Stan, M., Botnarciuc, V., Suceveanu, A., Mazilu, L., Costea, D., Suceveanu, A., Serban, D., Tudor, C., Mitroi, A., Brinzan, C., Voinea, F."Role of glutathione‑S‑transferase gene P1 in the diagnosis of prostate cancer in patients with ‘grey level’ prostate‑specific antigen values". Experimental and Therapeutic Medicine 24, no. 3 (2022): 591. https://doi.org/10.3892/etm.2022.11528